Abstract Number: 1491 • 2018 ACR/ARHP Annual Meeting
Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune and inflammatory polyarthritis involving mainly the synovial joints, and causing destruction of the articular cartilage and disabilities. Leflunomide…Abstract Number: 1492 • 2018 ACR/ARHP Annual Meeting
Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay
Background/Purpose: Available clinical tools do not adequately identify treatment non-responders in early rheumatoid arthritis (RA) leading to delayed disease control. Tools informed by molecular phenotype…Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…Abstract Number: 1495 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055) was a Phase 3b/4, 1-year, double-blind, triple-dummy, active comparator-controlled…Abstract Number: 1496 • 2018 ACR/ARHP Annual Meeting
Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis
Background/Purpose: Several prior studies have demonstrated poor clinical responses and reduced likelihood of achievement of remission among women with rheumatoid arthritis (RA). We aimed to…Abstract Number: 1497 • 2018 ACR/ARHP Annual Meeting
PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors
Background/Purpose: Rheumatoid arthritis (RA) is a complex disease affecting about 1.3M adults in the US. The patient population is very heterogeneous; no single drug mechanism…Abstract Number: 1498 • 2018 ACR/ARHP Annual Meeting
Serum MMP-3 More Than 155ng/Ml at Baseline Predicts One-Year Radiographic Progression in Patients with Rheumatoid Arthritis
Background/Purpose: Core disease activity indicators of rheumatoid arthritis (RA) have been found to be limited in predicting joint destruction progression. We previously reported that continuously…Abstract Number: 1499 • 2018 ACR/ARHP Annual Meeting
Elevated Serum MMP-3 in Remission Predicts Relapsed in Patients with Rheumatoid Arthritis
Background/Purpose: Our previous study showed continuously elevated serum matrix metalloproteinase (MMP)-3 predicted one-year radiographic progression (RP) in RA and the cutoff value at 6th month…Abstract Number: 1500 • 2018 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Background/Purpose: A multi-biomarker disease activity (MBDA) score was developed to objectively measure disease activity for patients with rheumatoid arthritis (RA).1 The MBDA score is calculated…Abstract Number: 1501 • 2018 ACR/ARHP Annual Meeting
Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate
Background/Purpose: The Multi-Biomarker Disease Activity (MBDA) score was developed to provide an objective measure of rheumatoid arthritis (RA) disease activity. Demonstrating moderate correlations with conventional…Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting
Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…Abstract Number: 1503 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model
Background/Purpose: Discontinuation of tumor necrosis factor inhibitor (TNFi) therapy in rheumatoid arthritis (RA) is attributable to various reasons. Above all, adverse event (AE) and insufficient…Abstract Number: 1504 • 2018 ACR/ARHP Annual Meeting
Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Background/Purpose: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define “seropositive” rheumatoid arthritis (RA). Both predict disease course, development of extra-articular features and treatment outcomes.…Abstract Number: 1505 • 2018 ACR/ARHP Annual Meeting
The Point-of-Care Ichroma Anti-CCP Test Showed a Competitive Measurement Accuracy, in Comparison to the Conventional Automated Tests
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibody test is a very important test for the diagnosis of rheumatoid arthritis (RA), but one of the disadvantages of the…
ACR Meeting Abstracts